NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) shares shot up 7.4% during trading on Tuesday . The company traded as high as $14.47 and last traded at $14.41. 367,691 shares changed hands during trading, a decline of 59% from the average session volume of 894,080 shares. The stock had previously closed at $13.42.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on NEO. The Goldman Sachs Group raised their price target on NeoGenomics from $17.00 to $19.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. TD Cowen lowered their target price on NeoGenomics from $22.00 to $19.00 and set an "outperform" rating on the stock in a report on Friday, December 29th. William Blair reaffirmed an "outperform" rating on shares of NeoGenomics in a report on Wednesday, February 21st. Piper Sandler lifted their target price on NeoGenomics from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Monday, February 26th. Finally, Needham & Company LLC lifted their target price on NeoGenomics from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, NeoGenomics currently has an average rating of "Moderate Buy" and a consensus price target of $19.50.
Check Out Our Latest Stock Report on NeoGenomics
NeoGenomics Price Performance
The stock has a 50 day moving average of $15.08 and a two-hundred day moving average of $15.91. The stock has a market cap of $1.81 billion, a PE ratio of -20.23 and a beta of 1.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.95 and a current ratio of 6.20.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $155.55 million for the quarter, compared to analysts' expectations of $152.90 million. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. Equities analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Insiders Place Their Bets
In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.96, for a total value of $38,701.52. Following the transaction, the general counsel now owns 34,866 shares in the company, valued at approximately $521,595.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company's stock.
Hedge Funds Weigh In On NeoGenomics
A number of large investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its holdings in shares of NeoGenomics by 9.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,247 shares of the medical research company's stock valued at $334,000 after purchasing an additional 1,791 shares during the period. Banque Cantonale Vaudoise grew its stake in shares of NeoGenomics by 6.6% in the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company's stock valued at $251,000 after buying an additional 993 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of NeoGenomics by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company's stock valued at $136,000 after buying an additional 1,791 shares in the last quarter. First Light Asset Management LLC grew its stake in shares of NeoGenomics by 29.6% in the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company's stock valued at $63,535,000 after buying an additional 897,843 shares in the last quarter. Finally, Burkett Financial Services LLC bought a new stake in shares of NeoGenomics in the 4th quarter valued at approximately $46,000. Institutional investors and hedge funds own 98.50% of the company's stock.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Recommended Stories
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
